This study aimed to determine whether immunohistochemical analysis of the Keap1/NRF2 pathway—by assessing basal NRF2 and peroxiredoxin 6 expression in tumor biopsies—could serve as a prognostic biomarker for treatment response and survival in patients with non-HPV-induced oropharyngeal SCC.In squamous cell carcinomas of the oropharynx, apart from HPV status, no reliable prognostic biomarkers are currently available. The gene discussed is PRDX6; the disease is neoplasm.